Clinical trials: Trachoma
Trachoma, Chlamydia
Tripartite International Research for the Elimination of Trachoma
Mass antimicrobial administrations have been remarkably successful in reducing the prevalence of the ocular strains of Chlamydia that cause trachoma.
- Trial name
- TIRET (NCT01202331)
- Testing
- mass treatment with oral azithromycin
- Where
- Ethiopia
- Volunteers
- 29,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Trachoma
Sanitation, Water, and Instruction in Face-washing for Trachoma I/II
SWIFT I is a series of 3 cluster-randomized trials designed to assess several alternative strategies for trachoma control in communities that have been treated with many years of mass azithromycin distributions.
- Trial name
- SWIFT I/II (NCT02754583)
- Testing
- Water, sanitation, and hygiene (WASH) intervention, Standard of care WASH intervention, Azithromycin
- Where
- Ethiopia
- Volunteers
- 47,605 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Child Mortality, Azithromycin
Resiliency Through Azithromycin for Children (REACH), Côte d'Ivoire
The aim of the study is to gather preliminary evidence on the operational feasibility and acceptability of integrating bi-annual mass drug administration (MDA) of single-dose azithromycin for children ages 1 to 11 months in high…
- Trial name
- REACH (NCT04617626)
- Testing
- Azithromycin
- Where
- Côte d’Ivoire
- Volunteers
- 1,735 people, healthy volunteers welcome
- Sponsor
- FHI 360
Corneal Opacity
Comparison of Ultrasonic Pachymetry With Orbscan in Corneal Haze
This study is planned to compare the results of ultrasonic and Orbscan pachymetry in corneal haze not related to surgery. Corneal haze is graded with slit-lamp by a single examiner.
- Trial name
- NCT00439114
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Baskent University
Trachoma, Chlamydia
Trachoma Amelioration in Northern Amhara (TANA)
The WHO has initiated a program to eliminate trachoma, blinding eye infection caused by Chlamydia trachomatis, in large part by mass distributions of oral azithromycin.
- Trial name
- TANA (NCT00322972)
- Testing
- Mass treatment with oral azithromycin to an entire community
- Where
- Ethiopia
- Volunteers
- 33,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Trachoma
Study of Three Alternatives for Mass Treatment in Trachoma Villages of Tanzania
After single, yearly, mass treatment of communities with azithromycin for active trachoma, what is the added effectiveness for reduction of trachoma and ocular C.
- Trial name
- NCT00347607
- Testing
- community surveillance and re-treatment
- Where
- 2 sites in United States, Tanzania
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Childhood Mortality
Mortality Reduction After Oral Azithromycin: Morbidity Study
The long-term goal of this study is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood morbidity and increasing growth, and for the potential selection of antibiotic…
- Trial name
- MORDORMorb (NCT02048007)
- Testing
- Azithromycin
- Where
- 6 sites in United States, Malawi and 3 more
- Volunteers
- 72,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Trachoma
Azithromycin Reduction to Reach Elimination of Trachoma B
The investigators propose a randomized controlled trial of discontinuation versus continuation of annual mass azithromycin distribution in hypoendemic communities of Maniema, DRC.
- Trial name
- ARRET (NCT06289647)
- Testing
- Azithromycin
- Where
- Democratic Republic of the Congo
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Trachoma, Lymphatic Filariasis
Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis
Trachoma and lymphatic filariasis (LF) are two 'Neglected Tropical Diseases' (NTDs), infectious diseases that affect millions of poor people in countries in the developing world.
- Trial name
- AZIVAL2 (NCT01903057)
- Testing
- azithromycin, ivermectin, albendazole
- Where
- Mozambique
- Volunteers
- healthy volunteers welcome
- Sponsor
- Emory University
Trachoma, Chlamydia Trachomatis
Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger
Trachoma is a disease of poverty, which in the hyperendemic areas affects all individuals by the time they are two years old. Active disease is concentrated in children and occurs sporadically in adults.
- Trial name
- NCT00618449
- Testing
- Azithromcyin, Azithromycin
- Where
- 2 sites in United States, Niger
- Volunteers
- 1,139 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Trachoma
Trachoma Elimination Study by Focused Antibiotic (TESFA)
The study population consists of all households residing in eligible kebeles (sub-districts) within districts in Amhara National Regional State which are identified as having a high prevalence of trachoma and infection measured…
- Trial name
- NCT03523156
- Testing
- Azithromycin mass treatment, Azithromycin targeted treatment
- Volunteers
- healthy volunteers welcome
- Sponsor
- Emory University
Trachoma
Azithromycin in Control of Trachoma II
Trachoma is the world's leading cause of preventable blindness. This disease, caused by Chlamydia trachomatis, is endemic in many parts of the developing world.
- Trial name
- NCT00286026
- Testing
- Azithromycin
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Trachoma
Azithromycin Reduction to Reach Elimination of Trachoma
The investigators propose a randomized controlled trial of discontinuation versus continuation of annual mass azithromycin distribution in hypoendemic communities of Maradi, Niger.
- Trial name
- ARRET (NCT04185402)
- Testing
- Azithromycin
- Where
- Niger
- Volunteers
- 3,931 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Trachoma
Water Uptake for Health in Amhara Pilot
Trachoma is a blinding disease caused by ocular strains of Chlamydia trachomatis. The Carter Center and Proctor Foundation have been jointly conducting trachoma research in the Goncha Siso Enese woreda of Amhara for the past 8…
- Trial name
- WUHA (NCT02373657)
- Testing
- instruction in soap-making and hygiene education
- Where
- Ethiopia
- Volunteers
- 4,068 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Trachoma
Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma
Musca sorbens, a fly that feeds from ocular and nasal discharge on humans, is thought to be the vector of trachoma. We are developing methods of fly control that specifically target this species, in the hope of interrupting Ct…
- Trial name
- NCT03813069
- Testing
- IR3535, Permethrin lower dose, Permethrin higher dose
- Where
- 2 sites in Ethiopia, United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Active Trachoma
The Effects of Hand and Face Washing With Soap on Active Trachoma Among Children 1-9 Years Old.
Active trachoma remains a major public health problem among children in Ethiopia. This clinical trial evaluates whether regular hand and face washing with soap reduces the prevalence of active trachoma among children aged 1-9…
- Trial name
- NCT07767578
- Testing
- A structured Health Belief Model (HBM)-based behavioural intervention delivered over 24 weeks, comprising interactive health education, behaviour change communication, skills training, and practical d
- Volunteers
- 990 people, healthy volunteers welcome
- Sponsor
- Bahir Dar University
Trachoma
Safety and Immunogenicity of a Chlamydia Vaccine CTH522
CHLM-02 was a phase I, double-blind, randomized, placebo-controlled trial of the chlamydia vaccine CTH522. 65 trial participants were randomized into 12 groups and six cohorts (A1 to F2).
- Trial name
- CHLM-02 (NCT03926728)
- Testing
- CTH522-CAF01 IM, CTH522-CAF09b IM, CTH522 ID
- Where
- United Kingdom
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Trachoma
Enhancing the A in SAFE for Trachoma
This study will assess the cost and feasibility of two strategies of enhanced Mass Drug Administration (MDA) of Zithromax to treat trachoma in the Republic of South Sudan.
- Trial name
- NCT05634759
- Testing
- Azithromycin for Routine Community-wide MDA, Two Additional Rounds of Azithromycin for Children, Azithromycin for Second Community-wide MDA
- Where
- South Sudan
- Volunteers
- 34,630 people, healthy volunteers welcome
- Sponsor
- Emory University
Survival of Flies Developing in Faecal Samples
Evaluation of the Impact of Oral Ivermectin on Musca Sorbens Flies, Putative Vector of Trachoma
Trachoma is caused by repeated Chlamydia trachomatis infection in the eye. Routes of infection include close person-to-person contact and contaminated clothing.
- Trial name
- IVERMUSC (NCT07657143)
- Testing
- Ivermectin
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Trachoma
Partnership for Rapid Elimination of Trachoma
Trachoma, an ocular infection caused by C. trachomatis, is the second leading infectious cause of blindness worldwide. Years of repeated infection with C.
- Trial name
- PRET (NCT00792922)
- Testing
- Azithromycin
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University